And

are now a part of the new and improved

search Created with Sketch.
search Created with Sketch.

Advertisement

Dermwire News

DermWireTV: Clinical Support Tech Data; Dupixent, Stelara Updates; Rihanna Launches Fenty Skin thumbnail
Play Button

DermWireTV: Clinical Support Tech Data; Dupixent, Stelara Updates; Rihanna Launches Fenty Skin

Series: DermWire TV | August 13, 2020

A feasibility study in collaboration between LEO Innovation Lab, VisualDX, and the German Association of Dermatological Prevention supports technology to assist in diagnosis of skin conditions. Leo Pharma’s investigational JAK inhibitor delgocitinib cream is  Fast Tracked by the FDA for the potential treatment of adults with moderate-to-severe chronic hand eczema. Two new studies reinforce the efficacy and safety of Dupixent for the treatment of atopic dermatitis in children and adults. Stelara is now approved for pediatric patients, 6-11 years of age, with moderate to severe plaque psoriasis. Look for Rihanna’s new Fenty Skin line under the umbrella of skincare offerings. 

Watch Video

News | August 13, 2020

InMode Introduces the Morpheus8 Platform and the Morpheus8 Body Fractional Technology

InMode Ltd. is introducing the Morpheus8 Body handpiece and Morpheus8 Platform.  Morpheus8 Body is a full-body fractional technology that delivers RF energy up to a thermal depth of 8mm (7mm pin depth + an additional 1mm thermal...

Read More

News | August 13, 2020

Estée Lauder Companies and Atropos Therapeutics Partner to Discover Botanical Senomodulators

The Estée Lauder Companies and Atropos Therapeutics are joining forces to discover botanical senomodulators or senescence-modulating chemicals. Atropos Therapeutics Inc. has a proprietary platform to identify and develop...

Read More

News | August 12, 2020

Laseroptek Introduces Pallas UVB Laser in US

South Korea-based Laseroptek Co., Ltd. is launching the Pallas Solid-State 311nm UVB laser for the treatment of vitiligo, psoriasis, atopic dermatitis and leukoderma in the United States.  Pallas allows the choice of either 308 or...

Read More

News | August 11, 2020

Verrica Enters Agreement with Lytix for Oncolytic Peptide for Dermatology

Verrica Pharmaceuticals Inc. has entered into an exclusive worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica intends to focus initially on basal cell and...

Read More

Advertisement

The Latest News

Advertisement

View more